Consider Cardiovascular Benefits When Recommending a GLP-1 Agonist
August 2019
Trulicity (dulaglutide) will be the third GLP-1 agonist to show CV benefits in some patients with type 2 diabetes.
It joins Ozempic (semaglutide) and Victoza (liraglutide). All three lower CV risk in type 2 patients with CV disease or at high CV risk.
Each of these meds also seems to slow progression to albuminuria...but isn't shown to delay dialysis.
Get concise advice on drug therapy, plus unlimited access to CE
Hospital Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote